Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Apr;175(4):1347-52.
doi: 10.1016/S0022-5347(05)00640-3.

Circulating chromogranin a and hormone refractory prostate cancer chemotherapy

Aurélie Cabrespine  1 , Laurent Guy, Françoise Gachon, Hervé Curé, Philippe Chollet, Jacques-Olivier Bay
Affiliations

Circulating chromogranin a and hormone refractory prostate cancer chemotherapy

Aurélie Cabrespine et al. J Urol. 2006 Apr.

Abstract

Purpose: Neuroendocrine differentiation is a frequent pattern in prostate adenocarcinoma. CgA seems to be a useful indicator of neuroendocrine differentiation in patients with HRPC. We evaluated the clinical interest of circulating CgA in HRPC.

Materials and methods: Serum CgA was assessed by immunoradiometric assay in 39 patients with HRPC treated with paclitaxel and carboplatin or mitoxantrone. Baseline CgA and its variation during chemotherapy were studied.

Results: Increased serum CgA was observed in 45% of patients. Previous local radiotherapy and the duration of hormonal therapy were independent factors that influenced CgA. There was no correlation between CgA and prostate specific antigen. Increased serum CgA showed positive predictive significance but no prognostic value. The chemotherapy response correlated with a CgA decrease of greater than 25%.

Conclusions: The current study suggests that CgA assessment facilitates patient selection by predicting the chemotherapy response and providing complementary information to follow the chemotherapy response.

PubMed Disclaimer

Publication types